BioArctic
234.2 SEK -0.51%6 investors are following this company
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Revenue
616M
EBIT %
41.01 %
P/E
90.08
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BIOA B
Daily low / high price
229.4 / 235.4
SEK
Market cap
20.69B SEK
Turnover
17.33M SEK
Volume
74K
Latest videos
Financial calendar
Interim report
29.08.2024
Interim report
14.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Lars Lannfelt | 33.4 % | 49.2 % |
Pär Gellerfors | 21.6 % | 32.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioArctic: Leqembi[®] (lecanemab) launched in China
BioArctic: FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioArctic: Leqembi[®] approved for the treatment of Alzheimer's disease in South Korea
Bulletin from the Annual General Meeting in BioArctic AB (publ)
![BioArctic, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/86b2a76b-da7c-417b-a4f5-3ee79a630844.png)